Interleukin-3 receptor signaling is a driver of myeloid leukaemia and a significant therapeutic target

Interleukin-3 受体信号传导是髓系白血病的驱动因素，也是重要的治疗靶点

• 批准号: nhmrc : GNT1103244
• 负责人: A/Pr Paul Ekert
• 金额: $ 60.2万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/interleukin-3-receptor-therapeutic-target/1346273
• 关键词: Interleukin; receptor; signaling; driver; myeloid

Acute Myeloid Leukaemia (AML) is an aggressive blood cancer. There are many types of AML, but overall, less than half of those with AML are cured. This project evaluates how certain molecules on the surfaces of leukaemic cells keep those cells alive and growing. We are also testing new ways to block these molecules and so provide new therapies for this cancer.

急性髓性白血病（AML）是一种侵袭性血癌。AML有很多种类型，但总的来说，只有不到一半的AML患者被治愈。这个项目评估了白血病细胞表面的某些分子是如何使这些细胞存活和生长的。我们也在测试阻断这些分子的新方法，从而为这种癌症提供新的治疗方法。